Seer Showcases AI-Driven Multi-Cancer Screening at ASMS 2026
Event summary
- Seer to present AI-driven multi-cancer screening approach at ASMS 2026, May 31–June 4.
- Collaboration with Korea University analyzing 20,000 clinical plasma samples using Proteograph Product Suite.
- Introduction of Radiant DIA™, a next-generation proteomics search engine, at the conference.
- Customer-led presentations to highlight applications in biomarker discovery and precision medicine.
The big picture
Seer's participation at ASMS 2026 underscores the growing importance of AI-driven proteomics in precision medicine. The company's collaboration with Korea University and the introduction of Radiant DIA highlight the shift towards scalable, unbiased proteomic insights. This trend is critical for advancing biomarker discovery and population-scale health initiatives, positioning Seer as a key player in the evolving proteomics landscape.
What we're watching
- AI Integration
- How AI-driven proteomics will impact multi-cancer screening scalability and accuracy.
- Data Processing
- Whether Radiant DIA can significantly reduce runtime while maintaining data sensitivity.
- Market Adoption
- The pace at which Seer's Proteograph platform will be adopted for population-scale research.
Related topics